6-(5-fluoro-2-methylphenyl)-6-methyl-4-trifluoromethylhept-1-yn-4-ol | 849354-28-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 6-(5-fluoro-2-methylphenyl)-6-methyl-4-trifluoromethylhept-1-yn-4-ol
• 英文别名: 2-(1,1-Dimethyl-3-hydroxy-3-trifluoromethyl-5-hexynyl)-4-fluorotoluene；6-(5-fluoro-2-methylphenyl)-6-methyl-4-(trifluoromethyl)hept-1-yn-4-ol
• CAS: 849354-28-5
• 化学式: C₁₆H₁₈F₄O
• 分子量: 302.312
• InChiKey: HOCGJJSCUIIIIZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  6-(5-fluoro-2-methylphenyl)-6-methyl-4-trifluoromethylhept-1-yn-4-ol 在 盐酸 、 甲醇 、 bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide 、 palladium on activated charcoal 、 potassium tert-butylate 、 氢气 、 三乙胺 作用下， 以 N-甲基吡咯烷酮 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 62.0h， 生成
  参考文献：
  名称：

  Optimization of Drug-Like Properties of Nonsteroidal Glucocorticoid Mimetics and Identification of a Clinical Candidate

  摘要：

  A series of nonsteroidal dissociated glucocorticoid receptor agonists was optimized for drug-like properties such as cytochrome P450 inhibition, metabolic stability, aqueous solubility, and hERG ion channel inhibition. This effort culminated in the identification of the clinical candidate compound (R)-39.

  DOI：

  10.1021/ml500387y
• 作为产物：
  描述：

  间溴苯甲醚 在 magnesium 、 氢化铝 、 mercury dichloride 作用下， 以 四氢呋喃 为溶剂， 反应 23.0h， 生成 6-(5-fluoro-2-methylphenyl)-6-methyl-4-trifluoromethylhept-1-yn-4-ol
  参考文献：
  名称：

  Optimization of Drug-Like Properties of Nonsteroidal Glucocorticoid Mimetics and Identification of a Clinical Candidate

  摘要：

  A series of nonsteroidal dissociated glucocorticoid receptor agonists was optimized for drug-like properties such as cytochrome P450 inhibition, metabolic stability, aqueous solubility, and hERG ion channel inhibition. This effort culminated in the identification of the clinical candidate compound (R)-39.

  DOI：

  10.1021/ml500387y

文献信息

• [EN] 1,1,1-TRIFLUORO-4-PHENYL-4-METHYL-2-(1H-PYRROLO<br/>[FR] DERIVES DE 1,1,1-TRIFLUORO-4-PHENYL-4-METHYL-2-(1H-PYRROLO-2,3-C PYRIDIN-2-YLMETHYL)PENTAN-2-OLE ET COMPOSES ASSOCIES EN TANT QUE LIGANDS DE GLUCOCORTICOIDES POUR LE TRAITEMENT DE MALADIES INFLAMMATOIRES ET DE DIABETE
  申请人：BOEHRINGER INGELHEIM PHARMA

  公开号：WO2005030213A1

  公开（公告）日：2005-04-07

  Compounds of Formula (IA), IB), IC), and (ID) wherein R1, R2, R3, R4, R5, and R6 are as respectively defined herein for Formula (IA), (IB), (IC), and (ID), or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.

  式(I A)、(IB)、(IC)和(ID)的化合物，其中R1、R2、R3、R4、R5和R6分别如本文所定义的式(I A)、(IB)、(IC)和(ID)，或其互变异构体、前药、溶剂化合物或盐；含有这些化合物的药物组合物，以及利用这些化合物调节糖皮质激素受体功能的方法，以及利用这些化合物治疗由糖皮质激素受体功能介导或以炎症、过敏或增殖过程为特征的疾病状态或病情的方法。
• Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof
  申请人：Bekkali Younes

  公开号：US20050176706A1

  公开（公告）日：2005-08-11

  Compounds of Formula (IA), (IB), (IC), and (ID) wherein R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are as respectively defined herein for Formula (IA), (IB), (IC), and (ID), or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.

  化合物的公式为（IA），（IB），（IC）和（ID），其中R1，R2，R3，R4，R5和R6分别定义为公式（IA），（IB），（IC）和（ID）中所述，或其互变异构体，前药，溶剂化物或盐; 包含这些化合物的药物组合物以及使用这些化合物调节糖皮质激素受体功能的方法和治疗由糖皮质激素受体功能介导或以炎症，过敏或增生过程为特征的疾病状态或病情的方法。
• Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof
  申请人：Harcken Christian

  公开号：US20090325988A1

  公开（公告）日：2009-12-31

  Compounds of Formula (I) wherein R 1 , R 2 , X, and Y are as defined herein, or a tautomer, optical isomer, prodrug, co-crystal, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.

  化合物的公式（I），其中R1，R2，X和Y的定义如本文所述，或其互变异构体，光学异构体，前药，共晶体或盐；含有这些化合物的药物组合物，以及使用这些化合物调节糖皮质激素受体功能的方法，治疗由糖皮质激素受体功能介导或以炎症，过敏或增殖过程为特征的疾病状态或病情的方法。
• Nonsteroidal Dissociated Glucocorticoid Agonists Containing Azaindoles as Steroid A-Ring Mimetics
  作者：Doris Riether、Christian Harcken、Hossein Razavi、Daniel Kuzmich、Thomas Gilmore、Jörg Bentzien、Edward J. Pack、Donald Souza、Richard M. Nelson、Alison Kukulka、Tazmeen N. Fadra、Ljiljana Zuvela-Jelaska、Josephine Pelletier、Roger Dinallo、Mark Panzenbeck、Carol Torcellini、Gerald H. Nabozny、David S. Thomson

  DOI：10.1021/jm100751q

  日期：2010.9.23

  Syntheses and structure activity relationships (SA R) of nonsteroidal glucocorticoid receptor (GR) agonists are described. These compounds contain azaindole moieties as A-ring mimetics and display various degrees of in vitro dissociation between gene transrepression and transactivation. Collagen induced arthritis studies in mouse have demonstrated that in vitro dissociated compounds (R)-16 and (R)-37 have steroid-like anti-inflammatory properties with improved metabolic side effect profiles, such as a reduced increase in body fat and scrum insulin levels, compared to steroids.
• [EN] GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF<br/>[FR] MIMÉTIQUES DE GLUCOCORTICOÏDES, LEURS PROCÉDÉS DE FABRICATION, DES COMPOSITIONS PHARMACEUTIQUES ET LEURS UTILISATIONS
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2009149139A8

  公开（公告）日：2011-02-24